Radiochemical purity was greater than 98%, and total synthesis time was ~90 min.Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G. Lancet. 2013 Jan 12;381(9861):93-4.BACKGROUND: Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes.

We compared the efficacy and safety of exenatide once weekly with liraglutide once daily in patients with type 2 diabetes.METHODS: We did a 26 week, open-label, randomised, parallel-group study at 105 sites in 19 countries between Jan 11, 2010, and Jan 17, 2011. Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg). Participants and investigators were not masked to treatment assignment. The primary endpoint was change in glycated haemoglobin (HbA(1c)) from baseline to week 26. Analysis was by intention to treat. This trial is registered with ClinicalTrials.

gov, FINDINGS: Of 912 randomised patients, 911 were included in the intention-to-treat analysis (450 liraglutide, 461 exenatide). The least-squares mean change in HbA(1c) was greater in patients in the liraglutide group (-1·48%, SE 0·05; n=386) than in those in the exenatide group (-1·28%, 0·05; 390) with the treatment difference (0·21%, 95% CI 0·08-0·33) not meeting predefined non-inferiority criteria (upper limit of CI <0·25%). The most common adverse events were nausea (93 [21%] in the liraglutide group vs 43 [9%] in the exenatide group), diarrhoea (59 [13%] vs 28 [6%]), and vomiting 48 [11%] vs 17 [4%]), which occurred less frequently in the exenatide group and with decreasing incidence over time in both groups. 24 (5%) patients allocated to liraglutide and 12 (3%) allocated to exenatide discontinued participation because of adverse INTERPRETATION: Both once daily liraglutide and once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with liraglutide. These findings, plus differences in injection frequency and tolerability, could inform therapeutic decisions for treatment of patients with FUNDING: Eli Lilly and Company and Amylin Pharmaceuticals LLC.Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study.of Rochester School of Medicine and Dentistry, Box 693, 601 Elmwood Ave, of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

OBJECTIVE: Glucagon-like peptide (GLP-1) analogs promote diabetes control and weight loss. Most GLP-1 analogs also lower adverse cardiovascular outcomes, making them ideal agents for patients with severe mental illness. The objective of this study was to analyze diabetic patients taking antipsychotic medications, comparing those on GLP-1 analogs with those on other diabetes treatments.METHODS: A total of 46 patients referred to outpatient diabetes clinics between July 2010 and April 2017 who were prescribed antipsychotic medications during the entire study period were included in this retrospective analysis. Eleven (24%) patients were started on a GLP-1 analog (cases), and 35 (76%) were treated with alternative antidiabetic agents (controls).RESULTS: Cases and controls did not differ in age, sex, height, weight, or medical therapies at the time of referral. Within 1 year, a reduction in mean ± SE glycosylated hemoglobin (HbA1c) levels was noted for both groups (cases: -16% ± 07%, controls: -17% ± 05%).

However, while patients on GLP-1 analogs lost 77 ± 22 kg, control patients gained 13 ± 14 kg (P < 5). Blunted HbA1c reductions were also noted in patients who took antipsychotic medication in addition to antidepressant medication (on antidepressant medication [n = 22]: -07% ± 09%, off antidepressant medication [n = 9]: -27% ± 0%, P < 01). This observation did not apply to patients treated with GLP-1 analogs, as they had larger HbA1c reductions than patients on alternative regimens (controls [n = 15]: -06% ± 0%, cases [n = 7]: -13% ± CONCLUSIONS: GLP-1 analogs promote both diabetes and weight control in diabetic patients on antipsychotic medications with or without antidepressant GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications.Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.Center at Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. glucagon-like peptide 1 investigates the various pharmacologic treatments for overweight and obesity in adults, especially glucagon-like peptide 1 (GLP-1) agonists.